Journal
TRANSFUSION
Volume 61, Issue 4, Pages 1160-1170Publisher
WILEY
DOI: 10.1111/trf.16321
Keywords
CCP; convalescent plasma; CoV2T; COVID-19; neutralizing antibody; SARS-CoV-2
Categories
Funding
- CTS Board of Directors Research Fund
Ask authors/readers for more resources
The efficacy of COVID-19 convalescent plasma (CCP) is believed to be linked to the concentration of neutralizing antibodies (nAb) to SARS-CoV-2. A study found that using surrogate binding antibody (bAb) signal-to-cutoff ratios (S/Co) to predict nAb titers can be effective, but the accuracy of the prediction decreases as target nAb titers increase.
Background Efficacy of COVID-19 convalescent plasma (CCP) is hypothesized to be associated with the concentration of neutralizing antibodies (nAb) to SARS-CoV-2. High capacity serologic assays detecting binding antibodies (bAb) have been developed; nAb assays are not adaptable to high-throughput testing. We sought to determine the effectiveness of using surrogate bAb signal-to-cutoff ratios (S/Co) in predicting nAb titers using a pseudovirus reporter viral particle neutralization (RVPN) assay. Methods CCP donor serum collected by three US blood collectors was tested with a bAb assay (Ortho Clinical Diagnostics VITROS Anti-SARS-CoV-2 Total, CoV2T) and a nAb RVPN assay. Prediction effectiveness of various CoV2T S/Co criteria was evaluated for RVPN nAb NT50 titers using receiver operating characteristics. Results Seven hundred and fifty-three CCPs were tested with median CoV2T S/Co and NT50 of 71.2 of 527.5. Proportions of donors with NT50 over target nAb titers were 86% >= 1:80, 76% >= 1:160, and 62% >= 1:320. Increasing CoV2T S/Co criterion reduced the sensitivity to predict NT50 titers, while specificity to identify those below increased. As target NT50 titers increase, the CoV2T assay becomes less accurate as a predictor with a decline in positive predictive value and rise in negative predictive value. Conclusion Selection of a clinically effective nAb titer will impact availability of CCP. Product release with CoV2T assay S/Co criterion must balance the risk of releasing products below target nAb titers with the cost of false negatives. A two-step testing scheme may be optimal, with nAb testing on CoV2T samples with S/Cos below criterion.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available